Settle Genetics is a biotechnology company that was established with the aim of developing an antibodies-based anticancer therapy. The industry is the leader in the production of antibody-drug therapies that are meant to utilize the ability of monoclonal antibodies to carry agents capable of killing the rapidly growing cells. The antibody-drug conjugates are designed to avoid attacking the normal cells of the body, hence directing their effect to the cancer cells. The adverse reactions that result from these agents are minimized by their selectivity towards the abnormally growing cancer cells in the body.
The first class of drugs to be developed under the antibody-drug conjugates was the brentuximab vedotin. The drug was developed in collaboration with the Takeda Pharmaceutical Limited Company, and it is recognized in more than 60 countries around the world. The anti-cancer agent is under clinical studies to determine its ability to be used in the management of CD-30 expressing lymphomas such as Hodgkin Lymphoma, Cutaneous T-cell lymphoma, and mature T-cell lymphoma as well as B-cell lymphomas. Seattle Genetics has been granted full commercialization rights to brentuximab vedotin due to its collaboration with Takeda Pharmaceutical Limited Company. Another agent under development is the vadastuximab talirine that is being evaluated for a possible effect in individuals with acute myeloid leukemia. Apart from brentuximab vedotin and vadastuximab talirine, other antibody-drug conjugates are still under development.
Seattle Genetics was co-founded by Clay Seagall back in 1998. Clay Seagall is the current Chief Executive Officer and the president of the biotechnology company. He plays a significant role in overseeing the company’s development of clinical and preclinical agents that are targeting the different types of cancers as mentioned above. The company is a bigger player in the market the production of antibody-drug conjugates. Dr. Seagall was behind the success of the company’s fundraising activities that saw the company raising more than 330 million US Dollars via both public and private financing. The company has also signed deals with major businesses in the market such as Genentech collaboration for SGN-40, the deal was valued at over 860 million United States Dollars.
Doctor Clay Seagall attended The University of Maryland from where he graduated with a B.S in Zoology. He also has a Ph.D. in genetics from George Washington University.